

CLAIMS

1. A pharmaceutical composition comprising an anti-VEGFR-2 antibody that specifically binds to VEGFR-2 to neutralize an activity of VEGFR-2, for treating, preventing, or alleviating cerebral edema.
- 5 2. The pharmaceutical composition according to claim 1, wherein the anti-VEGFR-2 antibody comprises:
 - a light chain variable region comprising light chain CDR1 of SEQ ID NO: 1, light chain CDR2 of SEQ ID NO: 2, and light chain CDR3 of SEQ ID NO: 3; and
 - a heavy chain variable region comprising heavy chain CDR1 of SEQ ID NO: 4, heavy chain CDR2 of SEQ ID NO: 5, and heavy chain CDR3 of SEQ ID NO: 6.
- 10 3. The pharmaceutical composition according to claim 1, wherein the anti-VEGFR-2 antibody comprises:
 - a light chain variable region of SEQ ID NO: 7; and
 - a heavy chain variable region of SEQ ID NO: 8.
- 15 4. The pharmaceutical composition according to claim 1, wherein the anti-VEGFR-2 antibody is a TTAC-0001 antibody or an antibody specifically binding to the same epitope as the epitope bound by the TTAC-0001 antibody.
5. The pharmaceutical composition according to claim 1, wherein the cerebral edema is a glioblastoma surrounding edema.
- 20 6. The pharmaceutical composition according to claim 1, wherein the composition further comprises one or more selected from the group consisting of osmotic agents, diuretics, glycerols and steroid agents.
7. The pharmaceutical composition according to claim 6, wherein the steroid agent is one or more selected among dexamethasone, cortisol, prednisone, prednisolone, methylprednisolone, triamcinolone, corticosterone and desonide.
- 25 8. The pharmaceutical composition according to claim 1, wherein the composition prolongs a survival time of a subject suffering from cerebral edema.

9. A pharmaceutical composition for reducing one or more of dosage and duration of administration of a steroid agent in a subject receiving the steroid agent to treat, prevent or alleviate cerebral edema, comprising an anti-VEGFR-2 antibody that specifically binds to VEGFR-2 to neutralize an activity of VEGFR-2

5 10. The pharmaceutical composition according to claim 9, wherein the anti-VEGFR-2 antibody comprises:

a light chain variable region comprising light chain CDR1 of SEQ ID NO: 1, light chain CDR2 of SEQ ID NO: 2, and light chain CDR3 of SEQ ID NO: 3; and

10 a heavy chain variable region comprising heavy chain CDR1 of SEQ ID NO: 4, heavy chain CDR2 of SEQ ID NO: 5, and heavy chain CDR3 of SEQ ID NO: 6.

11. The pharmaceutical composition according to claim 9, wherein the anti-VEGFR-2 antibody comprises:

a light chain variable region of SEQ ID NO: 7; and

a heavy chain variable region of SEQ ID NO: 8.

15 12. The pharmaceutical composition according to claim 9, wherein the anti-VEGFR-2 antibody is a TTAC-0001 antibody or an antibody specifically binding to the same epitope as the epitope bound by the TTAC-0001 antibody.

13. The pharmaceutical composition according to claim 9, wherein the subject is a subject suffering from glioblastoma.

20 14. The pharmaceutical composition according to claim 9, wherein the route of administration of steroid agent is oral administration.

15. The pharmaceutical composition according to claim 9, wherein the composition prolongs a survival time of the subject.

CLAIMS

1. A pharmaceutical composition comprising an anti-VEGFR-2 antibody that specifically binds to VEGFR-2 to neutralize an activity of VEGFR-2, for treating or alleviating cerebral edema, in which the anti-VEGFR-2 antibody comprises:
 - 5 a light chain variable region comprising light chain CDR1 of SEQ ID NO: 1, light chain CDR2 of SEQ ID NO: 2 and light chain CDR3 of SEQ ID NO: 3; and
 - a heavy chain variable region comprising heavy chain CDR1 of SEQ ID NO: 4, heavy chain CDR2 of SEQ ID NO: 5 and heavy chain CDR3 of SEQ ID NO: 6.
2. A pharmaceutical composition according to Claim 1, in which the anti-VEGFR-2
10 antibody comprises:
 - a light chain variable region of SEQ ID NO: 7; and
 - a heavy chain variable region of SEQ ID NO: 8.
3. A pharmaceutical composition according to Claim 1, in which the cerebral edema is a glioblastoma surrounding edema.
- 15 4. A pharmaceutical composition according to Claim 1, in which the composition further comprises one or more selected from the group consisting of osmotic agents, diuretics, glycerols and steroid agents.
5. A pharmaceutical composition according to Claim 4, in which the steroid agent is one or more selected among dexamethasone, cortisol, prednisone, prednisolone, methylprednisolone,
20 triamcinolone, corticosterone and desonide.
6. A pharmaceutical composition according to Claim 1, in which the composition prolongs a survival time of a subject suffering from cerebral edema.
7. A pharmaceutical composition for reducing one or more of dosage and duration of administration of a steroid agent in a subject receiving the steroid agent to treat or alleviate
25 cerebral edema, comprising an anti-VEGFR-2 antibody that specifically binds to VEGFR-2 to neutralize an activity of VEGFR-2, in which the anti-VEGFR-2 antibody comprises:
 - a light chain variable region comprising light chain CDR1 of SEQ ID NO: 1, light chain CDR2 of SEQ ID NO: 2 and light chain CDR3 of SEQ ID NO: 3; and

a heavy chain variable region comprising heavy chain CDR1 of SEQ ID NO: 4, heavy chain CDR2 of SEQ ID NO: 5 and heavy chain CDR3 of SEQ ID NO: 6.

8. A pharmaceutical composition according to Claim 7, in which the anti-VEGFR-2 antibody comprises:

- 5 a light chain variable region of SEQ ID NO: 7; and
 a heavy chain variable region of SEQ ID NO: 8.

9. A pharmaceutical composition according to Claim 7, in which the subject is a subject suffering from glioblastoma.

10 10. A pharmaceutical composition according to Claim 7, in which the route of administration of steroid agent is oral administration.

11. A pharmaceutical composition according to Claim 7, in which the composition prolongs a survival time of the subject.